SEC Tracker
Get the app
CSTL · XBRL financial data

Castle Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CSTL's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers61,49366,120*72,97487,00285,78286,311*87,98886,18883,04387,010*83,679103,546
Cost of revenue11,31912,423*13,89414,51915,60916,183*16,38317,62618,70418,315*20,53323,700
Research and development12,92312,994*13,80914,13612,32311,773*12,58812,78712,96013,515*14,42814,543
Selling, general and administrative44,61944,090*48,49551,08850,49949,965*58,62058,06555,90756,731*64,89966,122
Operating income (loss)(9,640)(5,658)*(5,471)5,0125,0794,050*(27,928)(4,251)(6,804)(3,827)*(18,407)(3,070)
Interest income2,7693,119*2,9963,1443,4043,372*3,0992,9442,8332,896*2,5452,356
Interest expense22*1421619292*892424*134193
Other income (expense)—year only——00*004896*(439)(153)
Income tax expense (benefit)3239*45(1,034)6,013(1,705)*(423)(4,666)115(382)*109370
Net income (loss)(6,905)(2,580)*(2,534)8,9202,2699,590*(25,848)4,523(501)(2,332)*(14,522)(2,060)
Earnings per share, basic USD per share(0.26)(0.10)*(0.09)0.320.080.34*(0.90)0.16(0.02)(0.08)*(0.49)(0.07)
Earnings per share, diluted USD per share(0.26)(0.10)*(0.09)0.310.080.31*(0.90)0.15(0.02)(0.08)*(0.49)(0.07)
Weighted average shares, basic thousands of shares26,83427,029*27,48527,64627,84028,128*28,60928,91429,07329,339*29,88930,399
Weighted average shares, diluted thousands of shares26,83427,029*27,48528,73829,40131,371*28,60929,54529,07328,715*29,88930,399

Balance sheet

CSV

Fiscal quarters (CSTL's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents91,22398,84182,94985,57294,959119,70989,68982,23385,556116,72963,76462,116
Marketable securities138,530144,258156,264174,116184,826173,421185,462193,697201,986182,776197,921204,689
Marketable securities, non-current—————05,570—————
Accounts receivable37,00338,30242,69945,98850,26151,21856,35352,31149,48243,38242,26448,341
Inventory5,7697,9427,6458,0136,5728,1356,8498,3668,65010,25410,46110,580
Prepaid and other current assets7,0976,2926,2216,7168,1547,67111,03512,06111,8957,95614,49115,374
Total current assets279,622295,635295,778320,405344,772360,154349,388348,668357,569361,097328,901341,100
Property and equipment, net22,273———————————
Right-of-use asset11,61312,30611,96111,62111,90411,58411,16415,50315,15114,79514,42414,196
Goodwill10,70010,70010,70010,70010,70010,70010,70010,70010,70010,70010,70010,700
Total assets436,019453,340458,507487,312514,565531,235501,715544,729562,786578,556547,805561,177
Accounts payable6,92910,2689,3189,5406,8106,9018,50213,18112,21118,71115,0389,668
Current portion of long-term debt—00002781,1111,94404171,6672,917
Total current liabilities36,32447,66731,95939,45444,29549,39237,27450,89055,30868,67748,76156,509
Long-term debt—010,00010,00810,0159,7458,9218,09610,0499,6408,3997,158
Lease liability, non-current13,43514,17313,86413,64514,69114,34514,04925,37725,30225,21725,11624,894
Total liabilities50,23662,07156,04563,41973,51075,40061,40989,35395,740107,68386,38991,147
Accumulated deficit(215,791)(218,371)(220,905)(211,985)(209,716)(200,126)(225,974)(221,451)(221,952)(224,284)(238,806)(240,866)
Total stockholders' equity385,783391,269402,462423,893441,055455,835440,306455,376467,046470,873461,416470,030
Total liabilities and equity436,019453,340458,507487,312514,565531,235501,715544,729562,786578,556547,805561,177
Common shares outstanding (cover page) thousands of shares26,91127,45027,60727,73728,00728,51428,87229,00829,18929,73130,33030,550

Cash flows

CSV

Fiscal quarters (CSTL's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(6,905)(2,580)*(2,534)8,9202,2699,590*(25,848)4,523(501)(2,332)*(14,522)(2,060)
Stock-based compensation13,043*11,802*12,67513,179*13,027*11,439*11,17911,208*12,100*11,406*9,77611,589*
Depreciation and amortization3,174*3,224*3,3403,348*3,541*5,768*29,7643,414*3,816*3,777*3,9294,070*
Net cash from operating activities5,012*18,587*(6,835)23,998*23,338*24,365*(6,036)20,821*22,631*26,931*(22,129)15,201*
Purchases of property and equipment2,455*3,793*9,1525,229*6,378*7,567*4,7409,263*14,834*7,184*12,4558,650*
Net cash from investing activities(9,708)*(7,672)*(19,701)(21,417)*(14,789)*5,770*(22,431)(28,378)*(18,389)*8,831*(25,803)(15,963)*
Net cash from financing activities45*(3,297)*10,64442*838*(5,385)*(1,553)101*(919)*(4,589)*(5,033)(886)*
Net change in cash(4,651)*7,618*(15,892)2,623*9,387*24,750*(30,020)(7,456)*3,323*31,173*(52,965)(1,648)*

Compare with peers

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Castle Biosciences62,116103,54615,201*30.5M— 10-QJun 30, 2026
Personalis98,27125,596(27,072)*108.4M6.7 quarters 10-QSep 30, 2026
BillionToOne548,628109,4489,136*not reported— 10-QJun 30, 2026
Celcuity182,049not reported(55,426)*48.9M13.6 quarters 10-QJun 30, 2026
Fortrea Holdings220,600691,50060,800*96.5M— 10-QSep 30, 2026
CareDx250,480139,36212,718*52.5M— 10-QSep 30, 2026
Fulgent Genetics26,30585,389(23,758)*27.5M10.8 quarters 10-QJun 30, 2026
Lumexa Imaging Holdings69,705264,16232,801*96.1M— 10-QJun 30, 2026
Veracyte299,521150,32145,826*80.4M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.